Withdrawal of Alupent

The short-acting bronchodilator orciprenaline sulphate (Alupent) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA.

It concluded that the adverse events associated with the drug outweigh its clinical benefits.

Patients who are currently receiving Alupent should be switched to a more selective ß2-agonist, such as salbutamol or terbutaline, as soon as possible.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more